Metastatic Malignant Neoplasm in the Liver Clinical Trial
Official title:
Stereotactic Body Radiotherapy for Liver Metastases and Hepatocellular Carcinoma Utilizing an MRI-Guided Tri-60Co Teletherapy System
Verified date | March 2022 |
Source | Jonsson Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer. SBRT is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Combining MRI with SBRT may help doctors to highlight the tissues surrounding the tumor better.
Status | Completed |
Enrollment | 21 |
Est. completion date | January 1, 2022 |
Est. primary completion date | January 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients may have either metastatic lesions from another primary site or primary hepatocellular carcinoma; patients with one histologically confirmed metastatic lesion of the liver who are presenting for local therapy for lesions concerning for metastases that cannot or should not be biopsied will also be considered for enrollment on a case by case basis; patients can simultaneously receive treatment for multiple hepatic lesions meeting the prior two requirements, at the discretion of the treating radiation oncologist - Karnofsky performance status (KPS) >= 70 - No active infections requiring systemic antibiotics - If a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the study - Ability to understand and willingness to sign a written informed consent Exclusion Criteria: - Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study - Refusal to sign the informed consent - Patients who are participating in a concurrent treatment protocol - Patients for whom a plan meeting institutional quality criteria cannot be designed for SBRT treatment via the MRI-guided teletherapy unit, but for whom an SBRT plan meeting institutional quality criteria can be designed for a conventional linear accelerator |
Country | Name | City | State |
---|---|---|---|
United States | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Jonsson Comprehensive Cancer Center | Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plan quality of the MRI guided radiotherapy vs. conventional linac radiotherapy. | Comparing the plan quality of the MRI guided radiotherapy to conventional determined by the ability to create treatment plans that are comparable to those generated by a conventional linear accelerator, and by the treating radiation oncologist's ability to accurately visualize and align to the target lesion | Up to 2 years | |
Primary | Feasibility of SBRT delivery by the MRI-guided tri-60Co teletherapy system, calculated by recording the number of patients for whom plans were or were not comparable between the two modalities | Up to 2 years | ||
Primary | Magnitude of target motion in three dimensional space as captured by real time imaging acquired by the MRI guided tri-60 Co teletherapy system | Up to 2 years | ||
Primary | Velocity of target motion in three dimensional space as captured by real time imaging acquired by the MRI guided tri-60 Co teletherapy system | Up to 2 years | ||
Primary | Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI | Up to 2 tears | ||
Secondary | Collection of biomarkers that may be associated with an immunologic systemic response to SBRT | Up to 2 years | ||
Secondary | DSS | Up to 2 years | ||
Secondary | Frequency of acute grade 2-5 gastrointestinal toxicity graded using the Common Toxicity Criteria version 4.0 | Up to 2 years | ||
Secondary | Infield tumor LC | Up to 2 years | ||
Secondary | OS | Up to 2 years | ||
Secondary | Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05863195 -
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
|
Phase 3 | |
Active, not recruiting |
NCT02156739 -
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
|
N/A | |
Recruiting |
NCT05039632 -
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02738606 -
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
|
Phase 2 | |
Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
Completed |
NCT00862680 -
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
|
||
Active, not recruiting |
NCT02070549 -
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
|
Phase 1 | |
Recruiting |
NCT03203525 -
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03844750 -
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
|
Phase 2 | |
Recruiting |
NCT06449937 -
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
|
N/A | |
Recruiting |
NCT04982653 -
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
|
Phase 2 | |
Active, not recruiting |
NCT02626312 -
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
|
Phase 1 | |
Active, not recruiting |
NCT02364557 -
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03457948 -
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
|
Phase 2 | |
Recruiting |
NCT04796818 -
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
|
N/A | |
Recruiting |
NCT06016855 -
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 4 |